

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1069)**

- (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON 31 DECEMBER 2025;  
(2) RETIREMENT OF DIRECTORS;  
(3) CHANGE OF CHAIRMAN OF THE BOARD;  
(4) CHANGE IN COMPOSITIONS OF THE BOARD COMMITTEES;  
AND  
(5) NON-COMPLIANCE WITH LISTING RULES**

Reference is made to the notice of the annual general meeting (the “**AGM**”) of China Health Technology Group Holding Company Limited (the “**Company**”) dated 9 December 2025 (the “**Notice**”) and the circular (the “**Circular**”) of the Company dated 9 December 2025. Capitalised terms used in this announcement shall have the same meanings as those defined in the Notice and the Circular unless otherwise defined herein.

The board of Directors (the “**Board**”) of the Company is pleased to announce that at the AGM held at Unit No. 2808-10 on 28th Floor of West Tower Shun Tak Centre, Nos. 168-200 Connaught Road Central, Hong Kong on Wednesday, 31 December 2025 at 11:00 a.m., all the proposed resolutions (the “**Resolutions**”) as set out in the Notice were duly passed by the Shareholders by way of poll.

Ms. Bu Xue attended the AGM in person and Mr. Guo Zhonglong and Mr. Chau Wing Nam attended the AGM by electronic means.

The poll results are as follows :

Ordinary Resolutions		Number of Votes (%)		Total number of votes cast
		For	Against	
1.	To receive and adopt the audited financial statements of the Company, the reports of the Directors and the independent Auditor for the year ended 30 June 2025.	9,182,000 100%	0 0%	9,182,000 100%
2.	Each as a separate resolution:			
	A. To re-elect Professor Fei Phillip as an executive Director;	0 0%	9,182,000 100%	9,182,000 100%
	B. to re-elect Mr. Guo Zhonglong as an independent non-executive Director; and	0 0%	9,182,000 100%	9,182,000 100%
	C. to re-elect Ms. Liu Shuhua as an independent non-executive Director.	9,182,000 100%	0 0%	9,182,000 100%
3.	To authorise the Board to fix the remuneration of the Directors.	9,182,000 100%	0 0%	9,182,000 100%
4.	To re-appoint Jon Gepsom CPA Limited, the Company's auditors and to authorise the Board to fix their remuneration.	8,932,000 100%	0 0%	8,932,000 100%
5.	To give a general mandate to the Directors to allot, issue or otherwise deal with additional shares (including any sale and transfer of treasury shares) not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	8,932,000 100%	0 0%	8,932,000 100%
6.	To give a general mandate to the Directors to buy back shares not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.	9,182,000 100%	0 0%	9,182,000 100%
7.	To extend the general mandate granted to the Directors to issue shares by the number of shares bought back (not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution).	9,182,000 100%	0 0%	9,182,000 100%
8.	To approve the adoption of the Share Scheme and the Scheme Mandate Limit (each as defined in the circular of the Company dated 9 December 2025) and to authorise the Directors to do such acts and things and enter into such transactions, arrangements and agreements as the Directors may in their sole discretion consider necessary, desirable or expedient in order to give full effect to and implement the Share Scheme.	9,182,000 100%	0 0%	9,182,000 100%

*Notes:*

- (a) The description of the above resolutions is by way of summary only. The full text of such resolutions appears in the Notice and the Circular.
- (b) The percentage of votes is based on the total number of Shares held by the Shareholders who voted at the AGM in person or by corporate representative or proxy.

As more than 50% of the votes were cast in favour of resolutions numbered 1, 2C, 3, 4, 5, 6, 7 and 8, resolutions numbered 1, 2C, 3, 4, 5, 6, 7 and 8 were duly passed as ordinary resolutions of the Company. As more than 50% of the votes were cast against resolutions numbered 2A and 2B, resolutions numbered 2A and 2B were not passed as ordinary resolutions at the AGM.

As at the date of the AGM, the total number of Shares in issue was 102,924,220, which was the total number of Shares entitling the Shareholders to attend and vote on the resolutions put forward at the AGM. There was no restriction on any Shareholders to vote only against the proposed resolutions at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules.

No Shareholders were required under the Listing Rules to abstain from voting on the resolutions at the AGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the AGM.

Tricor Investor Services Limited, the Company's Hong Kong branch share registrar, acted as the scrutineer for the vote-taking at the AGM.

## **RETIREMENT OF DIRECTORS**

As the resolution in relation to the re-election of Professor Fei Phillip (“**Professor Fei**”) as an executive Director and the resolution in relation to the re-election of Mr. Guo Zhonglong (“**Mr. Guo**”) as an independent non-executive Director were voted down at the AGM, the Board announces that Professor Fei will retire as an executive Director at the conclusion of the AGM and Mr. Guo will retire as an independent non-executive Director at the conclusion of the AGM. Each of Professor Fei and Mr. Guo has confirmed that he has no disagreement with the Board and there is no other matter in relation to their retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to express its sincere gratitude to Professor Fei and Mr. Guo for their valuable contribution to the Company during their tenure of service.

## **CHANGE OF CHAIRMAN OF THE BOARD**

Following the retirement of Professor Fei as an executive Director, the Board announces that Professor Fei has resigned as the chairman of the Board (the “**Chairman**”) with effect from 31 December 2025.

Professor Fei has confirmed that he has no disagreement with the Board and that he is not aware of any matters that need to be brought to the attention of the Shareholders or the Stock Exchange in relation to his resignation as the Chief Executive Officer. The Board would like to express its gratitude to Professor Fei for his significant contribution during his term of office as the Chairman.

The Board is pleased to announce that Ms. Bu Xue (“**Ms. Bu**”) has been appointed as the Chairman with effect from 31 December 2025.

The biography of Ms. Bu is as follows:

Ms. Bu, aged 36, was appointed as an independent non-executive Director on 14 August 2023 and was re-designated as an executive Director on 1 April 2025 and was appointed as the chief executive officer of the Company on 1 December 2025. Ms. Bu obtained her Bachelor’s degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People’s Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development.

Save as disclosed above, as at the date of this announcement, Ms. Bu (i) does not hold any other position with the Company or other members of the Group; (ii) does not have any relationship with the Directors, senior management, substantial or controlling shareholders (as defined in the Listing Rules) of the Company; (iii) has not held any directorship in any other public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas or other major appointments and professional qualifications; and (iv) does not have any interests in the shares, underlying shares and debentures of the Company which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Bu has entered into a contract of appointment as an executive Director with the Company for a term of one year with effect from 1 April 2025, subject to retirement and re-election at general meetings pursuant to the articles of association of the Company. Ms. Bu is entitled to receive a total annual remuneration of HK\$96,000 for her roles as an executive Director, the Chief Executive Officer and the Chairman. The remuneration is recommended by the remuneration committee of the Board (the “**Remuneration Committee**”) with reference to the remuneration policy of the Company, her duties and the prevailing market level of remuneration for executives of similar positions.

Save as disclosed above, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Ms. Bu as the Chairman that need to be brought to the attention of the Shareholders and the Stock Exchange in relation to her appointment.

## **CHANGE IN COMPOSITION OF NOMINATION COMMITTEE**

Following the retirement of Mr. Guo, he has ceased to be the chairman of the nomination committee of the Board (the “**Nomination Committee**”) and a member of each of the audit committee of the Board (the “**Audit Committee**”) and the Remuneration Committee with effect from 31 December 2025. Mr. Chau Wing Nam, an independent non-executive Director, has been appointed as the chairman of the Nomination Committee with effect from 31 December 2025. Ms. Bu Xue, an executive Director, has been appointed as a member of each of the Remuneration Committee and the Nomination Committee with effect from 31 December 2025.

## **NON-COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES**

According to Rule 3.10(1) of the Listing Rules, the Company is required to have at least three independent non-executive directors. According to Rule 3.21 of the Listing Rules, the Audit Committee must comprise a minimum of three members.

Following the retirement of Mr. Guo:

- (1) the Company only has two independent non-executive Directors, thus the number of independent non-executive Directors falls below the minimum number required under Rule 3.10(1) of the Listing Rules; and
- (2) the Audit Committee only has two members, thus the number of members falls below the minimum number required under Rule 3.21 of the Listing Rules.

In order to comply with the Listing Rules, the Company will use its best endeavours to identify suitable candidates to fill the vacancies on the Board, as soon as practicable and in accordance with Rule 3.10 and 3.21 of the Listing Rules, and in any event within three months from the effective date of retirement of Mr. Guo as required under Rule 3.11 and Rule 3.23 of the Listing Rules. The Company will make further announcement(s) as and when appropriate.

By Order of the Board  
**China Health Technology Group Holding Company Limited**  
**Ms. Bu Xue**  
*Chairman and Executive Director*

Hong Kong, 31 December 2025

*As at the date of this announcement and after conclusion of the AGM, the Board comprises Ms. Bu Xue as an executive Director; and Mr. Chau Wing Nam and Ms. Liu Shuhua as independent non-executive Directors.*